Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9152846 | 0.98 | TDP1 (0.45) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL124918 | 0.97 | TDP1 (0.42) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL2809739 | 0.97 | TDP1 (0.43) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL14488349 | 0.91 | TDP1 (0.39) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL13104003 | 0.90 | TDP1 (0.48) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL9715335 | 0.90 | TDP1 (0.40) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL8209723 | 0.90 | TDP1 (0.38) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL19652368 | 0.89 | TDP1 (0.37) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL12438502 | 0.89 | TDP1 (0.36) | TDP1BLMPMP22KDM4ELMNA | |
| SCHEMBL20143797 | 0.88 | TDP1 (0.35) | TDP1BLMPMP22KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288116-A1 | PSMA-TARGETING LIGANDS FOR MULTIMODAL APPLICATIONS | Stichting Radboud universitair medisch centrum (NL) | 2023-12-13 | — | — | EP | claimed |
| US-11835522-B2 | Sensors for detecting and imaging of cancer metastasis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-05 | — | — | US | claimed |
| CN-114832119-A | Radioactive gel microsphere and preparation method and application thereof | 苏州大学 | 2022-08-02 | — | — | CN | claimed |
| US-20220213165-A1 | THERAPEUTIC PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-07 | — | — | US | claimed |
| CN-114096848-A | Therapeutic peptides | 得克萨斯州大学系统董事会 | 2022-02-25 | — | — | CN | claimed |
| EP-3911753-A1 | SENSORS FOR DETECTING AND IMAGING OF CANCER METASTASIS | Massachusetts Institute of Technology (US) | 2021-11-24 | — | — | EP | claimed |
| WO-2020227620-A1 | THERAPEUTIC PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-11-12 | — | — | WO | claimed |
| US-20200232986-A1 | SENSORS FOR DETECTING AND IMAGING OF CANCER METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-07-23 | — | — | US | claimed |
| WO-2020150560-A1 | SENSORS FOR DETECTING AND IMAGING OF CANCER METASTASIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-07-23 | — | — | WO | claimed |
| CN-108358956-B | Fluorescent probe Eu III-dtpa-bis (adenine) and application thereof in detection of orotic acid in urine | 辽宁大学 | 2019-12-06 | — | — | CN | claimed |
| US-20010002419-A1 | Chemical modification of proteins to improve biocompatibility and bioactivity | AMGEN INC. | 2001-05-31 | — | — | US | claimed |
| US-6119701-A | USING A FILTER ELEMENT COMPRISING A POLYMER DERIVATIZED WITH ALDEHYDIC GROUPS, E.G., CELLULOSE DIALDEHYDE, DIALDEHYDE STARCHES; DETOXIFICATION WITHOUT REMOVAL OF THE NICOTINE AND FLAVOR; CIGARETTES, CIGARS, PIPES AND ROOM AIR FILTERS | CERAMI CONSULTING CORP. (US) | 2000-09-19 | — | — | US | claimed |
| EP-1003772-A1 | CHEMICAL MODIFICATION OF PROTEINS TO IMPROVE BIOCOMPATIBILITY AND BIOACTIVITY | Amgen Inc., (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999009052-A1 | CHEMICAL MODIFICATION OF PROTEINS TO IMPROVE BIOCOMPATIBILITY AND BIOACTIVITY | AMGEN INC. (US) | 1999-02-25 | — | — | WO | claimed |
| EP-0713602-A1 | SYNTHESIS OF POLYSACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS | ADVANCED MAGNETICS INCORPORATED (US) | 1996-05-29 | — | — | EP | claimed |
| WO-1995005669-A1 | SYNTHESIS OF POLYSACCHARIDE COVERED SUPERPARAMAGNETIC OXIDE COLLOIDS | ADVANCED MAGNETICS, INC. (US) | 1995-02-23 | — | — | WO | claimed |
| US-5262176-A | Synthesis of polysaccharide covered superparamagnetic oxide colloids | ADVANCED MAGNETICS, INC. (US) | 1993-11-16 | — | — | US | claimed |
| EP-0220858-B1 | MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES, CORRESPONDING HYBRIDOMAS, THE PRODUCTION AND USE THEREOF | CETUS CORP (US) | 1993-02-10 | — | — | EP | claimed |
| US-4938948-A | Diagnosis | CETUS CORPORATION (US) | 1990-07-03 | — | — | US | claimed |
| EP-0220858-A2 | Monoclonal anti-human breast cancer antibodies, corresponding hybridomas, the production and use thereof | CETUS ONCOLOGY CORPORATION (US) | 1987-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002419-A1 | Chemical modification of proteins to improve biocompatibility and bioactivity | PTMS, BMP2, NPEPPS | TDP1 3608/4885BLM 4331/4885PMP22 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.